<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="16828">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02156609</url>
  </required_header>
  <id_info>
    <org_study_id>PHPCEMark</org_study_id>
    <nct_id>NCT02156609</nct_id>
  </id_info>
  <brief_title>HeartMate® PHP CE Mark Clinical Investigation Plan</brief_title>
  <acronym>HM PHP CE Mark</acronym>
  <official_title>HeartMate® PHP CE Mark Clinical Investigation Plan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thoratec Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Thoratec Corporation</source>
  <oversight_info>
    <authority>Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products</authority>
    <authority>Paraguay: El Comite` de Bioetica de la Superintendencia de Salud</authority>
    <authority>Netherlands: Dutch Health Care Inspectorate</authority>
    <authority>Colombia: INVIMA Instituto Nacional de Vigilancia de Medicamentos y Alimentos</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The HeartMate PHP is a catheter-based pump designed to provide partial left heart
      circulatory support.  The study will assess the safety and performance of the HeartMate PHP
      in supporting patients who are hemodynamically unstable, or at risk of being hemodynamically
      unstable, while undergoing percutaneous coronary interventions (PCI), such as coronary stent
      placement.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The HeartMate PHP (percutaneous heart pump) is a catheter-based axial flow pump designed to
      provide partial left ventricular circulatory support.  The primary objective of this
      prospective, nonrandomized, multi-center, open-label trial is to assess the safety and
      performance of the HeartMate PHP in supporting patients who are hemodynamically unstable, or
      at risk of being hemodynamically unstable, while undergoing percutaneous coronary
      interventions (PCI).
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">October 2014</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Primary Endpoint</measure>
    <time_frame>Post procedure or at hospital discharge (whichever is longer), 30 days post procedure</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Primary Performance Endpoint:
Freedom from hemodynamic compromise during PCI procedure defined as: Mean Arterial Pressure (MAP) not falling below 60mm Hg for more than 10 minutes during the PCI procedure and additional pressor medication is not required.
Primary Endpoint will be evaluated at:
Post procedure or at hospital discharge (whichever is longer)
30 days post procedure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Composite of Major Adverse Events (MAE)</measure>
    <time_frame>Post procedure or at hospital discharge (whichever is longer), 30 days post procedure</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Primary Safety Endpoint:
Composite of Major Adverse Events (MAE):
device-related cardiac death,
new Q wave myocardial infarction,
surgical intervention due to device complication or malfunction,
device-related access site complication requiring intervention or device-related limb ischemia,
cerebral vascular accident (CVA),
new or worsening aortic valve insufficiency,
major bleeding complication (BARC 3 or &gt;),
severe hypotension
Primary Endpoint will be evaluated at:
Post procedure or at hospital discharge (whichever is longer)
30 days post procedure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary Endpoint</measure>
    <time_frame>Post procedure or at hospital discharge (whichever is longer), 30 days post procedure</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Efficacy of hemodynamic support as measured by:
Maximal decrease in cardiac power output (CPO) from baseline
Changes in central venous pressure from baseline (CVP)
Changes in pulmonary artery pressure from baseline (PAP)
Changes in pulmonary capillary wedge pressure from baseline (PCWP)
Changes in cardiac output from baseline (CO)
Changes in cardiac index from baseline (CI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Event Composites</measure>
    <time_frame>Post procedure or at hospital discharge (whichever is longer), 30 days post procedure</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Individual components of the major adverse event composites</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>High Risk Percutaneous Coronary Intervention</condition>
  <arm_group>
    <arm_group_label>Percutaneous coronary intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Percutaneous ventricular support with the HeartMate PHP during high risk percutaneous coronary intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Percutaneous ventricular support with the HeartMate PHP</intervention_name>
    <description>The HeartMate PHP device will be inserted percutaneously prior to the start of high risk coronary interventions (complex disease, reduced ejection fraction, etc.) to provide hemodynamic support,</description>
    <arm_group_label>Percutaneous coronary intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least 18 years of age.

          -  Patient presents with a non-emergent need for complex PCI with:

               1. an ejection fraction of ≤35% requiring hemodynamic support during the procedure,
                  AND

               2. the heart team has determined that the patient is not an optimal surgical
                  candidate, OR the patient elects not to undergo surgery

          -  Written, signed, and dated informed consent

        Exclusion Criteria:

          -  Emergent PCI

          -  ST elevation myocardial infarction within 7 days of procedure

          -  Cardiac arrest within 7 days of procedure requiring CPR or defibrillation

          -  Hemodynamic support with the HeartMate PHP post-PCI is anticipated

          -  Cardiogenic shock (SBP &lt;90 mmHg for &gt;1 hour with either cool clammy skin OR oliguria
             OR altered sensorium OR cardiac index &lt;2.2 L/min/m2)

          -  Mural thrombus in the left ventricle

          -  History of  aortic valve replacement

          -  Documented presence of aortic stenosis (orifice area of 1.5cm2 or less)

          -  Moderate to severe aortic insufficiency (echocardiographic assessment of aortic
             insufficiency graded as 2 or higher)

          -  Severe peripheral vascular disease

          -  Abnormalities of the aorta that would preclude surgery, including aneurysms and
             significant tortuosity or calcifications

          -  Planned use of rotablator or atherectomy during the procedure

          -  Serum creatinine &gt; 3.5mg/dL within 7 days of procedure

          -  Liver dysfunction with elevation of liver enzymes and bilirubin levels to ≥ 3x ULN or
             INR (Internationalized Normalized Ratio) ≥2

          -  Uncorrectable abnormal coagulation parameters

          -  Active systemic infection requiring treatment with antibiotics

          -  Clinically relevant stroke or TIA within 3 months of procedure. Patients with
             suspected stroke or TIA within 3 months of procedure must have documented absence of
             neurological infarction

          -  Uncontrollable allergy or intolerance to heparin, aspirin, clopidogrel, ionic and
             nonionic contrast media, or any other potentially required anticoagulants or
             antiplatelet therapy drugs

          -  History of heparin induced thrombocytopenia

          -  Patient is pregnant or planning to become pregnant during the study period

          -  Participation in another clinical study of an investigational drug or device that has
             not met its primary endpoint-
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dariusz Dudek, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jagiellonian University Medical College</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mark Macedo, BSN</last_name>
    <phone>781-852-8332</phone>
    <email>mmacedo@thoratec.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Instituto del Corazon</name>
      <address>
        <city>Bucaramanga</city>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sergio Higuera, MD</last_name>
      <email>seanhile@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Boris Vesga, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hector Hernandez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Juan Granada, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Erasmus Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <zip>3000 CA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>M. J. Lenzen, MD</last_name>
      <email>m.lenzen@erasmusmc.nl</email>
    </contact>
    <investigator>
      <last_name>Robert Jan M. van Geuns, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sanatorio Italiano</name>
      <address>
        <city>Asuncion</city>
        <country>Paraguay</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Adrian Ebner, MD</last_name>
      <email>adrian_ebner@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Adrian Ebner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Szpital (The Prof. Leszka Gieca Upper-Silesian Medical Centre)</name>
      <address>
        <city>Katowice</city>
        <zip>40-635</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sebastian Dworowy, MD</last_name>
      <email>sdworowy@wp.pl</email>
    </contact>
    <investigator>
      <last_name>Andrzej Ochala, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital in Krakow (John Paul II)</name>
      <address>
        <city>Krakow</city>
        <zip>31-202</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wioletta Grzegorzak</last_name>
      <email>wgrzegorzak@su.krakow.pl</email>
    </contact>
    <investigator>
      <last_name>Krzysztof Zmudka, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Cardinal Stefan Wyszynski Institute of Cardiology</name>
      <address>
        <city>Warszawa</city>
        <zip>04-628</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Adam Witkowski, MD, PhD</last_name>
      <email>witkowski@hbz.pl</email>
    </contact>
    <investigator>
      <last_name>Adam Witkowski, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jacek Rozanski, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Slaskie Centrum Chorob Serca w Zabrzu (Silesian Center for Heart Disease)</name>
      <address>
        <city>Zabrze</city>
        <zip>41-800</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marian Zembala, MD, PhD</last_name>
      <email>m.zembala@sccs.pl</email>
    </contact>
    <investigator>
      <last_name>Marian Zembala, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Colombia</country>
    <country>Netherlands</country>
    <country>Paraguay</country>
    <country>Poland</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <lastchanged_date>June 4, 2014</lastchanged_date>
  <firstreceived_date>May 29, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HeartMate PHP</keyword>
  <keyword>HeartMate PHP CE Mark</keyword>
  <keyword>Percutaneous coronary intervention</keyword>
  <keyword>PCI</keyword>
  <keyword>Percutaneous ventricular assist</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
